A carregar cotações...
Previsão
O preço-alvo médio dos analistas é € 6,55 (+49,20%). A mediana é € 5,71 (+30,07%).
| Comprar |
3 |
| Manter |
7 |
| Vender |
2 |
Notícias Ir para o feed de notícias
RxSight unveils turnaround plan and strengthens partnership with Alcon
At the Wells Fargo Healthcare Conference, new CEO Aziz Mottiwala presented a strategic realignment plan to intensify use of the light‑adjustable lens (LAL) among existing surgeons and to double U.S. sales through internal reallocations. The partnership closed in July with Alcon includes a $200 million upfront payment and a 30% royalty on future sales, plus access to Alcon’s sales network. RxSight has about $210 million in cash (excluding the full Alcon payment), high gross margins, and is working on a next‑generation LAL; the company is targeting a return to growth in 2027 but has not provided concrete forecasts. » Mais em de.investing.com
RxSight appoints Aziz Mottiwala as president and CEO
RxSight appointed Aziz Mottiwala, effective July 20, as president and chief executive officer; he replaces Dr. Ron Kurtz, who will move to chief medical officer and leave the board of directors, while Mottiwala will be named to the board. Mottiwala joins from Tarsus Pharmaceuticals and brings experience in senior sales and commercial roles in ophthalmology. The stock is under pressure (about −8% last week, −50% over six months) and is trading at $5.25 (market capitalization $216.92 million). The company manufactures the Light Adjustable Lens System and said it would not change its prior financial guidance. » Mais em de.investing.com
RxSight cuts 2026 revenue forecast after competitive pressure
RxSight lowered its 2026 revenue forecast to $110–120 million (previously $120–135 million), triggering a roughly 12.9% share price decline. The total revenue outlook of $140–160 million includes $30–40 million from the Alcon collaboration; preliminary Q2 revenues are expected at $32–34 million ( $5–7 million from the Alcon partnership, about $27 million from product sales). The company cited "significant commercial headwinds" and plans to accelerate sales investments while maintaining spending discipline; gross margin guidance was raised to 73–75%, and operating expenses remain at the high end of the $150–160 million range. Cash and equivalents totaled about $209 million as of June 30; RxSight is working on a next generation of Light Adjustable Lens products. » Mais em de.investing.com
Dados financeiros da empresa
| (EUR) | junho de 2026 | YoY |
|---|---|---|
| Receitas | 29,56 mi | 3,59% |
| Ganho bruto | 22,68 mi | 6,13% |
| Ganho líquido | -10,6 mi | 6,00% |
| EBITDA | -9,64 mi | 3,60% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 185,31 mi |
Número de ações | 41,59 mi |
Máximo/mínimo de 52 semanas | € 11,85 - € 3,94 |
| Dividendos | Não |
Beta | 1,14 |
PER (PE Ratio) | -4,40 |
PEG (PEG Ratio) | 0,13 |
P/VC (PB Ratio) | 0,78 |
P/V (PS Ratio) | 1,62 |
Perfil da empresa
A RxSight, Inc., uma empresa de tecnologia médica, dedica-se à investigação e desenvolvimento, fabrico e venda de lentes intraoculares ajustáveis por luz (LAL), utilizadas na cirurgia de catarata nos Estados Unidos e a nível internacional. Oferece o sistema RxSight, que permite aos médicos personalizar e melhorar a acuidade visual dos doentes após a cirurgia de catarata. O sistema RxSight da empresa inclui o dispositivo de aplicação de luz RxSight, um equipamento de tratamento por luz de consultório que emite luz UV num padrão programado para modificar a LAL com base na correção visual necessária para alcançar a visão desejada após a cirurgia de catarata. Destina-se sobretudo a oftalmologistas especializados em catarata. A empresa era anteriormente conhecida como Calhoun Vision, Inc. e mudou o nome para RxSight, Inc. em fevereiro de 2017. A RxSight, Inc. foi constituída em 1997 e tem sede em Aliso Viejo, Califórnia.
| Nome | RXSIGHT INC. DL -,001 |
| CEO | Aziz Mottiwala |
| Sede | Aliso Viejo,
ca EUA |
| Site | |
| Setor | Cuidados de saúde |
| Indústria | Cuidados de saúde: equipamentos e produtos |
| Entrada em bolsa | 30/07/2021 |
| Colaboradores | 461 |
Análise aprofundada
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NASDAQ | RXST |